1. Academic Validation
  2. Secreted phospholipase A2 modifies extracellular vesicles and accelerates B cell lymphoma

Secreted phospholipase A2 modifies extracellular vesicles and accelerates B cell lymphoma

  • Cell Metab. 2022 Apr 5;34(4):615-633.e8. doi: 10.1016/j.cmet.2022.02.011.
Kai Kudo 1 Yoshimi Miki 2 Joaquim Carreras 3 Shunya Nakayama 4 Yasushi Nakamoto 1 Masatoshi Ito 5 Etsuko Nagashima 1 Kei Yamamoto 6 Hiroshi Higuchi 7 Shin-Ya Morita 8 Asuka Inoue 9 Junken Aoki 10 Kiyoshi Ando 11 Naoya Nakamura 3 Makoto Murakami 12 Ai Kotani 13
Affiliations

Affiliations

  • 1 Department of Innovative Medical Science, Tokai University School of Medicine, Isehara, Japan; Division of Hematological Malignancy, Institute of Medical Sciences, Tokai University, Isehara, Japan.
  • 2 Laboratory of Microenvironmental Metabolic Health Sciences Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • 3 Department of Pathology, Tokai University School of Medicine, Isehara, Japan.
  • 4 Department of Innovative Medical Science, Tokai University School of Medicine, Isehara, Japan; Division of Hematological Malignancy, Institute of Medical Sciences, Tokai University, Isehara, Japan; Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
  • 5 Support Center for Medical Research and Education, Tokai University School of Medicine, Isehara, Japan.
  • 6 Division of Bioscience and Bioindustry, Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima, Japan.
  • 7 Center for Cancer Immunology, Cutaneous Biology Research Center, Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • 8 Department of Pharmacy, Shiga University of Medical Science Hospital, Otsu, Japan.
  • 9 Department of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
  • 10 Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.
  • 11 Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
  • 12 Laboratory of Microenvironmental Metabolic Health Sciences Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Electronic address: makmurak@m.u-tokyo.ac.jp.
  • 13 Department of Innovative Medical Science, Tokai University School of Medicine, Isehara, Japan; Division of Hematological Malignancy, Institute of Medical Sciences, Tokai University, Isehara, Japan. Electronic address: aikotani@k-lab.jp.
Abstract

Extracellular vesicles (EVs) including exosomes act as intercellular communicators by transferring protein and MicroRNA cargoes, yet the role of EV lipids remains unclear. Here, we show that the pro-tumorigenic action of lymphoma-derived EVs is augmented via secreted Phospholipase A2 (sPLA2)-driven lipid metabolism. Hydrolysis of EV Phospholipids by group X sPLA2, which was induced in macrophages of Epstein-Barr virus (EBV) lymphoma, increased the production of fatty acids, lysophospholipids, and their metabolites. sPLA2-treated EVs were smaller and self-aggregated, showed better uptake, and increased cytokine expression and lipid mediator signaling in tumor-associated macrophages. Pharmacological inhibition of endogenous sPLA2 suppressed lymphoma growth in EBV-infected humanized mice, while treatment with sPLA2-modified EVs reversed this phenotype. Furthermore, sPLA2 expression in human large B cell lymphomas inversely correlated with patient survival. Overall, the sPLA2-mediated EV modification promotes tumor development, highlighting a non-canonical mechanistic action of EVs as an extracellular hydrolytic platform of sPLA2.

Keywords

EBV Lymphoma; extracellular vesicle; lipid mediator; sPLA₂.

Figures
Products